Tremendous disparities are known to exist in cardiovascular disease and its related outcomes. Much of this can be traced to poorly controlled hypertension and its attendant, pressure-related consequences, especially target-organ cardiac damage. The latter, which occurs prematurely and disproportionately in African- Americans, reduces both quality and quantity of life. The risk of target-organ cardiac damage is particularly high among inner-city African-Americans with hypertension, particularly those who utilize the emergency department for chronic blood pressure management. Like cardiovascular disease, vitamin D deficiency disproportionately affects African-Americans. Vitamin D is thought to be an important modifier of cardiovascular disparities through its direct (and, via parathyroid hormone, indirect) myocardial (hypertrophy, fibrosis) and vascular (increased resistance, loss of compliance) effects. Vitamin D repletion in those who are deficient has been postulated as mechanism to reduce the cardiovascular disease burden experienced by African- Americans, especially if initiated early before irreversible damage has occurred, but this has yet to be tested in a prospective clinical trial. Accordingly, this proposal was designed to investigate the relationship between vitamin D and subclinical target-organ cardiac damage (as identified on cardiac magnetic resonance imaging) in a cohort of African-American, vitamin D deficient hypertensive patients without prior history of heart disease. Specifically, we seek to ascertain the effect of adjunct vitamin D therapy on left ventricular hypertrophy (primary aim), myocardial fibrosis and central vascular function (secondary aims) at one-year using a placebo controlled, randomized design. Antihypertensive treatment in both study arms will be standardized and our focus will be recruitment of patients who present to our safety-net institution with poorly controlled blood pressure - a high-risk, high-reward subset who would stand to benefit tremendously from identification of an inexpensive intervention, which could effectively reduce the adverse impact of hypertension.
African-Americans die younger and more often from hypertension and hypertensive heart disease than other races. Regression of left ventricular hypertrophy, a cardinal manifestation of elevated blood pressure, which disproportionately affects African-Americans, can reduce adverse events and, accordingly, has become a focal point of secondary prevention. Vitamin D deficiency may be an important contributor to racial differences in hypertensive heart disease but whether adjunct vitamin D therapy provides benefit is unknown.
|Fermann, Gregory J; Levy, Phillip D; Pang, Peter et al. (2017) Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department: GUIDED-HF (Get With the Guidelines in Emergency Department Patients With Heart Failure). Circ Heart Fail 10:|
|Barrett, Tyler W; Rising, Kristin L; Bellolio, M Fernanda et al. (2016) The 2016 Academic Emergency Medicine Consensus Conference, ""Shared Decision Making in the Emergency Department: Development of a Policy-relevant Patient-centered Research Agenda"" Diagnostic Testing Breakout Session Report. Acad Emerg Med 23:1354-1361|
|Brody, Aaron; Janke, Alex; Sharma, Vineet et al. (2016) Public Health, Hypertension, and the Emergency Department. Curr Hypertens Rep 18:50|
|Miller, Joseph B; Kinni, Harish; Amer, Ahmed et al. (2016) Therapies to Reduce Blood Pressure Acutely. Curr Hypertens Rep 18:43|
|Goldberg, Elizabeth M; Levy, Phillip D (2016) New Approaches to Evaluating and Monitoring Blood Pressure. Curr Hypertens Rep 18:49|
|Levy, Phillip; Mueller, Christian; Peacock, W Frank (2015) Comment on ""is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database"". J Card Fail 21:434-5|
|Brody, Aaron; Rahman, Tahsin; Reed, Brian et al. (2015) Safety and efficacy of antihypertensive prescription at emergency department discharge. Acad Emerg Med 22:632-5|
|Kumar, Vijaya Arun; Viau, David; Levy, Phillip (2015) New Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027. Curr Emerg Hosp Med Rep 3:66-73|
|McNaughton, Candace D; Self, Wesley H; Zhu, Yuwei et al. (2015) Incidence of Hypertension-Related Emergency Department Visits in the United States, 2006 to 2012. Am J Cardiol 116:1717-23|
|Collins, Sean; Storrow, Alan B; Albert, Nancy M et al. (2015) Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. J Card Fail 21:27-43|
Showing the most recent 10 out of 16 publications